Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.
The second trial site is at the Central Coast Local Health District in New South Wales.
It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.
Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。